Clinical Trial Detail

NCT ID NCT00538005
Title Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors San Diego Pacific Oncology & Hematology Associates
Indications

melanoma

Therapies

Bevacizumab + Oxaliplatin + Sorafenib

Age Groups: adult

No variant requirements are available.